Compass Pathways Plunges 27%: A Rival Just Beat It to the FDA

Compass Pathways (NASDAQ: CMPS) stock plunged 27.31% on Monday, November 2, 2026, closing at $8.41 — its worst single day since June 2025 — after a report that rival Usona Institute has finished submitting its own psilocybin treatment to the FDA, threatening Compass's lead in the race to bring a psychedelic therapy to market.

What happened

Shares of Compass Pathways fell $3.16 from Friday's close of $11.57 to end Monday at $8.41, a drop of 27.31%, on heavy volume of roughly 16.8 million shares. The selloff made Compass the biggest loser among U.S. stocks on the day. The stock bounced modestly in after-hours trading, rising about 4.6% to around $8.80, but remained far below where it started the session.

The trigger was competitive, not financial. According to a report from Psychedelic Alpha, cited widely in market coverage, the non-profit research organization Usona Institute has completed submitting its application to the U.S. Food and Drug Administration for a psilocybin treatment for major depressive disorder. That makes Usona's therapy the second psychedelic now under review by the agency — and investors immediately repriced the value of being first.

Why it's blowing up

Compass is developing COMP360, its proprietary synthetic psilocybin, for treatment-resistant depression — patients who have not responded to existing antidepressants. The company's investment case has rested heavily on timing: be first, or near-first, with an FDA-approved psilocybin therapy and capture a market that analysts believe could be worth billions. Compass has said it expects to complete its own full FDA submission in the fourth quarter of 2026.

Usona's completed submission scrambles that story. If a rival therapy is already fully filed — for major depressive disorder, a much larger patient population than treatment-resistant depression — the first-mover advantage Compass investors were paying for looks thinner. The pain spread across the sector: shares of Helus Pharma (HELP) fell about 18% on the same news, on track for its worst day since March 2026, as traders marked down psychedelic developers broadly.

The reaction was loud online as well as on the tape. On Stocktwits, retail sentiment on CMPS swung from neutral to bullish over 24 hours even as the price collapsed — dip-buyers arguing the drop was overdone — while message volume stayed at high levels.

Key facts

• The drop: CMPS closed down 27.31% at $8.41 on Monday, November 2, 2026, its worst day since June 2025, before rebounding about 4.6% after hours.
• The catalyst: Psychedelic Alpha reported Usona Institute has finished submitting an FDA application for psilocybin in major depressive disorder — the second psychedelic under FDA review.
• Compass's drug: COMP360, a synthetic psilocybin for treatment-resistant depression; the company expects to complete its full FDA submission in Q4 2026.
• Sector fallout: Helus Pharma (HELP) fell about 18% on the same report.
• Context: Even after Monday's plunge, CMPS was still up roughly 19% year-to-date, and the average analyst price target sits near $23 — though targets set before a competitive shock can move fast.

What's next

The timing could hardly be tighter: Compass reports third-quarter earnings on Tuesday, November 3, and Wall Street expects a loss of about $0.41 a share, according to Fiscal AI data cited in coverage. Management's update on the regulatory timeline — and any response to the Usona filing — will likely matter more than the numbers themselves. If Compass confirms its submission stays on track for this quarter, some of Monday's panic may unwind; if the timeline slips, the stock's first-mover premium has further to fall. This report describes what happened and why markets reacted; it is not a recommendation to buy, sell, or hold any security.

Sources: Stocktwits, TradingKey, StockAnalysis, The Motley Fool

FAQ

Why did Compass Pathways stock fall 27% on November 2, 2026?

Because Psychedelic Alpha reported that rival Usona Institute has finished submitting its psilocybin therapy to the FDA for major depressive disorder, undercutting Compass's expected first-mover advantage in psychedelic medicine.

What is COMP360?

COMP360 is Compass Pathways' proprietary synthetic psilocybin, in development for treatment-resistant depression. The company expects to complete its full FDA submission in the fourth quarter of 2026.

Was Compass the only psychedelic stock hit?

No. Helus Pharma (HELP) fell about 18% on the same news, as investors repriced the competitive timeline for psychedelic drug developers across the sector.

What happens next for CMPS?

Compass reports third-quarter earnings on Tuesday, November 3, 2026, when management is expected to update its FDA submission timeline — the update traders will weigh against Monday's selloff.